Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06377540 · ClinicalTrials.gov registry record · Phase 2
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
A Phase 2 study of Classic Hodgkin Lymphoma and Autologous Stem Cell Transplant, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT06377540 is a Phase 2 study of Classic Hodgkin Lymphoma and Autologous Stem Cell Transplant that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 28 participants, below the 250-participant average among 9 other Classic Hodgkin Lymphoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06377540, a Phase 2 study of Classic Hodgkin Lymphoma and Autologous Stem Cell Transplant, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2 single arm study to evaluate efficacy and safety of Pembrolizumab before with BEAM ASCT followed by Pembrolizumab maintenance for 1 year. Patients will receive 200 mg Pembrolizumab Q3week starting at day - 28 before stem cell transplant until 1 year after autologous stem cell transplant.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Carmustine
- PROCEDURE Autologous stem cell transplant
Study Locations (1)
Minnesota
- Masonic Cancer Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2024-12-04 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06377540
The ClinicalTrials.gov registry entry for NCT06377540 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 250-participant average among 9 other Classic Hodgkin Lymphoma trials with a reported enrollment target (89% lower). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Classic Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06377540 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06377540 about?
NCT06377540 is a clinical study titled "MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma". This is a Phase 2 single arm study to evaluate efficacy and safety of Pembrolizumab before with BEAM ASCT followed by Pembrolizumab maintenance for 1 year. Patients will receive 200 mg Pembrolizumab Q3week starting at day - 28 before stem cell transplant until 1 year after autologous stem cell trans...
What is the current status of trial NCT06377540?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2024-12-04. Estimated completion is 2027-09-01.
What conditions does trial NCT06377540 study?
This clinical trial studies the following conditions: Classic Hodgkin Lymphoma, Autologous Stem Cell Transplant.
What interventions are being tested in trial NCT06377540?
The interventions under investigation include: Pembrolizumab (DRUG), Etoposide (DRUG), Cytarabine (DRUG), Carmustine (DRUG), Autologous stem cell transplant (PROCEDURE).
Who is sponsoring clinical trial NCT06377540?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06377540 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Classic Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
RECRUITING · Phase 2
-
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.